SHARE

Belgium-Netherlands, Accelerator, 2018

EIT Health Belgium-Netherlands awards four start-ups with HeadStart Funding

15th August 2019

The selection was made from 28 high quality proposals

HeadStart Funding supports start-ups in taking their next step to the market by accelerating market entry and by creating new economic activity more effectively. In addition to the €50 000 cash award, EIT Health and its partners provide access to innovation facilities and networks as well as mentoring. Moreover, the grant will increase the possibility of attracting further private investment.

The four chosen start-ups are:

  • Epihunter – revealing absence seizures
    Epihunter creates digital connected solutions to make epilepsy matter less and life matter more. Their first solution helps children with absence seizures. Epihunter uses wearable EEG devices to reveal those seizures to the outside world. This allows the children to interact more naturally with the people around them.
  • Vitroscan – a drug response platform
    Vitroscan’s platform offers drug developers a tool to test novel drugs in series of cancer patients, to compare the response with standard care drugs and to characterise responsive patients in detail (clinical response, genetic analysis) thus improving the outcome of subsequent clinical trials.
  • Plasmacure – healing chronic wounds
    Plasmacure heals chronic wounds with a revolutionary, patented active treatment method. A special electronic pad creates a cold plasma above the wound that will kill bacteria, stimulate cell proliferation and improve local blood flow. The treatment takes one minute per day only, and is be repeated until healing. Self-management is possible.
  • STENTiT – minimally invasive vascular restoration
    Stentit’s regenerative stent will be the only device on the market that brings vascular regeneration to the patient, while preventing invasive surgical procedures. Made out of a fully biodegradable porous structure, the product provides minimally-invasive accessibility to treat the diseased artery and promotes natural vascular regeneration using the patient’s circulating blood cells.

EIT Health provides HeadStart funding twice a year. The upcoming second call for 2018 is due to close on 2 October.

For further enquiries contact:

  • Bart Haex, bart.haex@eithealth.eu

EIT Health helps Tubulis secure €10.7M in funding

EIT Health helps Tubulis secure €10.7M in funding

Investor Network aids firm doing antibody work

Find out more

EIT Health-backed start-ups garner big investments

EIT Health-backed start-ups garner big investments

A million each for iLoF and Restorative Neurotechnologies

Find out more

EIT Health aids 11 start-ups disrupted by COVID-19

EIT Health aids 11 start-ups disrupted by COVID-19

Start-up Rescue Instrument gives €5.5M in co-investment

Find out more